AI Assistant
Blog
Pricing
Log In
Sign Up
Evaluación económica de alemtuzumab comparado con natalizumab en el tratamiento de esclerosis múltiple remitente recurrente en Colombia
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
